T otal proctocolectomy with ileal pouch-anal anastomosis (IPAA) is a complex procedure. The procedure is mainly applied to patients with ulcerative colitis (UC), familial adenomatous polyposis, or occasionally Crohn's colitis who require surgery. 1 Various pouch conditions may affect long-term pouch outcomes, such as Crohn's disease (CD) of the pouch 2,3 and chronic pouchitis. 4, 5 Some nonpouch risk factors may also influence the outcomes of IPAA, such as excessive weight gain 6 and radiation injury for colitis-associated cancer. 7 The ileal pouch is located at the pelvis adjacent to the vagina in females or prostate in males. The incidence and prevalence of prostate cancer in patients with IPAA and the impact of the malignancy on pouch outcome are not known. Approximately 40% to 60% patients undergoing IPAA are men at an age range of 40 to 50 years. 1, 8 Prostate cancer is the most common malignancy in males in the United States and 12% of men in the United States had prostate cancer with the majority age between 55 and 74 years. 9 Our previous study of 932 cases with IPAA showed that prostate cancer accounted for 11% of newonset extraintestinal cancers after the pouch surgery. 10 The diagnosis of prostate cancer in patients with IPAA can be challenging, as the ileal pouch body is placed in the immediate vicinity of the prostate. 11 Digital examination of prostate is generally not recommended in these patients because of altered anatomy and scar tissue from the surgery. 12 The anatomic location of the ileal pouch may make the treatment of prostate cancer challenging, owing to the loss of normal anatomic tissue planes, denervation of pelvic musculature, and pelvic adhesions. 13 There are scant data in the literature in the impact of prostate cancer treatment on patient's IPAA function and quality of life (QOL). A small study of 16 patients with prostatectomy after IPAA reported that the overall pouch function status remained unchanged after prostate surgery in 3 patients with available data. 14 The aims of this study were to evaluate pouch-related outcomes after prostate cancer treatment and to assess the change in QOL of the patients.
PATIENTS AND METHODS

Patients
The study was approved by the Institutional Review Board (IRB) at the Cleveland Clinic Foundation. Patients who had both IPAA and prostate cancer treatment were identified from our prospectively maintained IRB-approved Pouch Database and Pouchitis Database by electronic query and field search in data on co-morbidities and follow-up. In addition, patients were also identified from an electronic health record (Epicsys, Verona, WI) as having (1) diagnosis of IBD (International Classification of Disease [ICD]-9-CM code: 555.xx or 556.xx) or pouchitis (ICD-9-CM code: 569.71) and (2) diagnosis of prostate cancer (ICD-9-CM code: 185) documented on electronic health record.
Study and Matched Controls
All patients with IPAA and prostate cancer were identified using the above-mentioned methods. Patients who underwent IPAA for UC, familial adenomatous polyposis, and colorectal cancer were all included. This information was further confirmed by review of electronic charts. Patients without information in either pouch-related outcomes or prostate cancer treatment were excluded. Patients with prostate cancer were matched with those without prostate cancer in the Pouch Database by sex, age (65 yr), and pouch duration (65 yr) in a 1 to 2 ratio. The inclusion and exclusion of patients for the cohort are listed in Figure 1 .
Study Variables
We reviewed electronic and paper-chart medical records for patient demographics and IBD-related characteristics (disease duration, diagnosis at the time of colectomy [UC versus Crohn's colitis versus indeterminate colitis], indication for colectomy, extent of colitis, and primary sclerosing cholangitis), and pouch-related variables (configuration of pouch, stage of pouch surgery, duration of pouch, pouch disease diagnosis, and current use of antitumor necrosis factor biologics or immunosuppressants).
Characteristics related to prostate cancer were also collected, including serum prostate-specific antigen level, the Gleason score, clinical and pathological stage of prostate cancer, and therapies for prostate cancer (surgery, brachytherapy, or hormonal therapy).
Assessment of Functional Outcomes and QOL of Pouch
Follow-up of patients in the database was routinely performed through telephone calls, mailed questionnaires, and office visits. Functional outcomes of IPAA were graded by asking patients the number of bowel movements during daytime or bedtime hours, urgency, and seepage (day/night). QOL was evaluated using the Cleveland Global Quality of Life scale (CGQL, range from 0 to 1, with 1 being the best). Patients were asked to rate 3 items (current QOL, current quality of health, and current energy level), each on a scale of 0 to 10 (0, worst; 10, best). The scores were added, and the final CGQL score was obtained by dividing this result by 30. The correlation of CGQL with the Short Form-36 Health Survey (SF-36) and its validity were described previously. 15 
Statistical Analysis
Pouch function and QOL were compared between pretreatment and posttreatment, between subjects and controls, and among different treatment modalities for prostate cancer. Descriptive analysis was performed to summarize all the data. This included mean and standard deviation or median and interquartile range for continuous factors and frequencies/percentages for categorical factors. Univariate analysis was performed with chisquare and Fisher's exact probability tests (for an expected cell count ,5). Paired t-tests or paired Wilcoxon rank-sum tests were used to compare pouch outcomes and QOL. Differences were considered statistically significant when P , 0.05.
RESULTS
The patient identification process is shown in a flow chart (Fig. 1) . Thirty-five patients were identified. A total of 30 eligible male patients were included after the exclusion of 5 patients because of the unavailable data pertaining to prostate cancer treatment. Patients with prostate cancer and IPAA in this cohort were matched (as evidenced by similar age and pouch duration) to 60 patients who had no prostate cancer (Table 1) . Most patients had IPAA for UC, of whom 4 (4/27, 14.8%) underwent IPAA for colitis-associated neoplasia, 2 had left-sided colitis while others had pancolitis. One patient with UC had primary sclerosing cholangitis.
Characteristics of Ileal Pouches
IPAA was constructed before the diagnosis of prostate cancer in 24 (80%) patients and during or after the diagnosis of prostate cancer in 6 (20%). Of the 6 patients, 4 (13.3/%) underwent pouch surgery after prostatectomy and 2 (6.7%) had synchronous prostatectomy and pouch construction. The duration from pouch construction to prostate cancer treatment was 10.5 6 6.8 years and duration from pouch construction to the most recent follow-up was 14 6 7.6 years. There were no statistically significant differences in the pouch configuration and stage of pouch surgery between the study and control groups.
Characteristics of Prostate Cancer
The total Gleason scores were 6 in 11 patients, 7 in 8 patients, 8 in 1 patient, and 10 in 1 patient. The Gleason scores were not available in the remaining 9 patients. prostate-specific antigen level was available in 21 patients with a mean of 10.3 6 8.8 (range, 1.5-30) ng/mL. The treatment modalities of prostate cancer included prostatectomy without external beam radiation (n ¼ 22, 73.3%), brachytherapy (n ¼ 5, 16.7%), watchful waiting (n ¼ 2, 6.7%), and hormonal therapy (n ¼ 1, 3.3%) (Fig. 1) .
Pouch Failure and Final Pouch Disease Conditions
Five (16.7%) patients developed pouch failure in the prostate cancer group requiring permanent diverting ileostomy. One patient developed a urethral-pouch fistula after synchronous completion proctectomy with IPAA and radical retropubic prostatectomy. This particular patient underwent permanent ileostomy 9 months after IPAA despite multiple attempts to repair the defect with suture and to perform pouch advancement flap and left gracilis flap graft. By contrast, the other patient undergoing synchronous pouch construction and prostatectomy had normal a pouch to date, 6 years after IPAA. The second patient had permanent diversion because of fecal incontinence 22 years after pouch construction and 14 years after brachytherapy for prostate cancer. The third patient developed radiation pouchitis from brachytherapy leading to pouch failure with a permanent diverting ileostomy. The fourth patient underwent prostatectomy for prostate cancer and had permanent diversion for pelvic abscess and advanced age (.80 yr old). The last one also had permanent diversion because of severe pouchitis from radiation therapy for underlying rectal cancer.
Kaplan-Meier analysis and log-rank test showed that the pouch failure was significantly increased as compared to the matched controls (P ¼ 0.04) (Fig. 2) . Although no statistically significant differences were found between the cases and controls in terms of final pouch condition, as detailed in Table 1 , there was a trend toward more anastomotic stricture in patients in the study group than in those in the control group.
Functional Outcomes and QOL
The median length of follow-up was 6 (interquantile range, 2.7-8) years after prostate cancer treatment. There were 16 patients (53.3%) with complete data on the pouch function and pouch-related QOL, preprostate and postprostate cancer treatment. One patient had IPAA for familial adenomatous polyposis and 1 patient for colorectal cancer, whereas the remaining 14 had IPAA for UC. Treatment modalities included radical retropubic prostatectomy (n ¼ 10), brachytherapy (n ¼ 3), watchful waiting (n ¼ 2), and hormonal therapy (n ¼ 1). No statistically significances were noticed in daytime and nighttime bowel movements, daytime seepage and nighttime seepage and the CGQL score (Table 2 ). There were no statistically significant differences in functional outcomes and QOL between patients in the study group and those in the control group (Table 3) or among different treatment modalities for prostate cancer (Tables 4 and 5 ). To evaluate the changes in pouch function and QOL overtime in the matched controls, comparisons were performed between most recent follow-up and the previous follow-up (Table 2 ) with an interval of 5.9 (0.8-12.5) years.
DISCUSSION
IPAA offers patients a better QOL by preserving the anal sphincter mechanism and route of natural passage of stool than a permanent end ileostomy. However, various complications may occur after pouch surgery, including pouchitis, anastomotic leak, pelvic abscess, and afferent limb syndrome. 16 The loss of tissue planes may also raise the concern for the injury to the pouch, resulting pouch-vesicular fistulas. In addition, therapeutic intervention for other concurrent disease may affect pouch-related outcomes as well. 7 Therefore, extra attention should be paid to the diagnostic process because of risk of pouch injuries, when prostate cancer is suspected. Transpouch prostatic biopsy may result in peripouch abscess despite a normal pouch at the time of biopsy 17 and transperineal template-guided prostate biopsy route may be a preferred approach. 12 In this study, we investigated the functional outcomes and QOL after diagnosis and treatment of prostate cancer in patients with IPAA. We found that the risk of pouch failure was significantly increased in the univariable analysis. However, there was no significant adverse impact of prostate cancer treatment on pouch outcomes in those who were able to retain their pouches. This study showed an increased rate of pouch failure (16.7%) in those undergoing prostate cancer treatment compared with those in the matched controls. The long-term pouch failure rate in general pouch population is reported to be ranging from 10% to 15%. 4 Furthermore, a trend toward an increased incidence of anastomotic stricture was also observed in these patients.
The impact of prostate cancer treatment on pouch outcomes has been previously evaluated in several small studies. 18 However, none of those studies revealed the association between prostate cancer treatment and pouch failure. In a retrospective review of 16 patients with prostatectomy after IPAA, Umbreit et al 14 reported successful prostatectomy in all patients without pouch violation or pouch-related postoperative complications; and the overall pouch function status was unchanged after the prostate surgery. However, detailed pouch function was available in only 3 patients in this case series. The technical difficulty after previous pelvic surgery may deter some surgeons from offering a radical prostatectomy. 19 Based on the findings of our study and the literature, we believe that radical prostatectomy can be performed in clinically indicated patients with meticulous caution to avoid devastating complications.
Brachytherapy is an effective treatment option in patients with localized prostate cancer. The use of external beam radiation is relatively contraindicated in patients with IPAA. The small intestinal mucosa (including mucosa of ileal pouch reservoir) has an increased radiosensitivity compared with the rectum. Therefore, the pouch made from the small intestine is more vulnerable than rectum. 20 We previously studied a group of 63 patients who underwent radiation therapy for colitisassociated cancer and found that pelvic radiation administered before IPAA construction was associated with poor pouch outcomes. 7 None of our patients with prostate cancer underwent brachytherapy before IPAA in this study. Significant complications have been reported in other settings, including genitourinary tract complications, radiation proctitis, or rectal ulcers. 21, 22 However, previous report of brachytherapy for prostate cancer in patients with IPAA showed no serious complications, such as pouch ulcers, fistulas, fecal incontinence, or pouch failure. 20 Williamson et al 20 reported pouch function after prostate brachytherapy in 5 patients with clinically localized prostate cancer who have undergone IPAA. Bowel frequency returned to the baseline by 4 months after the procedure. Complications, such as pouch ulcers, fistulas, or fecal incontinence, did not occur in those patients. However, in our study, 1 patient developed severe radiation pouchitis after brachytherapy, leading to permanent pouch diversion. In this study, we have 16 patients in the study group with available data on functional outcomes and QOL before and after the diagnosis and treatment of prostate cancer. Favorable pouch functional outcomes and noncompromised QOL after prostate cancer treatment were observed in those who retained their pouches. Therefore, we found that the diagnosis and treatment of prostate cancer in patients with IPAA may affect pouch survival. Discussion should be made regarding the risk of pouch failure among the patient and IBD specialists, colorectal surgeons and urologists once the diagnosis of prostate cancer is established. The evaluation of pouch functional status based on symptoms and routine pouchoscopy is advocated.
Limitations exist in this study. Although this is the largest series in the literature, the sample size of the study is small, which does not provide a sufficient statistical power to compare various other clinical outcomes among different treatment modalities. In addition, the sample size was not large enough to definitively show that the diagnosis and treatment of prostate cancer were independently associated with pouch failure. The overall rate of pouch failure in the study was not significantly higher than expected in the literature (10%-15%). It seems that pouch failure might not be associated with prostate cancer per se, but rather radiation therapy. Details regarding the treatment for prostate cancer were not assessed, such as nerve-sparing or nonnerve-sparing prostatectomy and the dosage of brachytherapy. Finally, dynamic changes in pouch function and possible evolution of disease diagnosis were also not assessable. Therefore, the impact of diagnosis and treatment of prostate cancer on pouch function cannot be comprehensively studied.
In conclusion, the risk for pouch failure may be increased after the diagnosis and treatment for prostate cancer in patients with IPAA. In patients who were able to retain their pouches, the pouch function and QOL did not seem to be adversely affected. 
